Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Research and development | 1,025,547 | 1,573,928 | 1,400,564 | 645,719 |
| Legal and professional | 538,536 | 780,427 | 1,322,002 | 526,877 |
| General and administrative | 2,346,323 | 596,886 | 328,995 | 310,038 |
| Total operating expenses | 3,910,406 | 2,951,241 | 3,051,561 | 1,482,634 |
| Net loss from operations | -3,910,406 | -2,951,241 | -3,051,561 | -1,482,634 |
| Change in fair value of marketable securities | - | - | -42,898 | -27,964 |
| Interest expense | - | 11,930 | 2,137 | 430,685 |
| Change in fair value of marketable securities | - | - | - | - |
| Interest income | 81 | - | 2,524 | 14,158 |
| Interest expense-Related Party | 2,614 | - | - | - |
| Interest expense-Nonrelated Party | 19,129 | - | - | - |
| Gain on sale of marketable securities | - | - | 56,398 | 39,683 |
| Change in fair value of derivative liabilities | 11,673 | 2,643 | 286,316 | -143,773 |
| Loss on settlement of convertible debt | - | - | 762,186 | - |
| Change in fair value of convertible notes | 213,930 | -92,479 | - | - |
| Total other income (expense) | 203,941 | -101,766 | -732,521 | -548,581 |
| Net loss | -3,706,465 | -3,053,007 | -3,784,082 | -2,031,215 |
| Net loss per shares - basic | -3.29 | -0.3 | -1.59 | -0.96 |
| Net loss per shares - diluted | -3.29 | -0.3 | -1.59 | -0.96 |
| Weighted average common shares outstanding - basic | 1,126,054 | 10,048,915 | 2,384,177 | 2,104,933 |
| Weighted average common shares outstanding - diluted | 1,126,054 | 10,048,915 | 2,384,177 | 2,104,933 |